P731.F MEDEXUS PHARMACEUTIC.

Healthcare Pharmaceuticals Frankfurt Exchange
3.52 EUR
Close of Nov 12, 2026
1.51 3.52
Market cap
EUR 111M
P/E
-
P/B
2.34x
ROE
4.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is P731.F undervalued?

Graham number

The Graham number of MEDEXUS PHARMACEUTIC. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MEDEXUS PHARMACEUTIC. fundamental analysis

No fundamental analysis for MEDEXUS PHARMACEUTIC. yet.

MEDEXUS PHARMACEUTIC. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MEDEXUS PHARMACEUTIC.

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile id…

Full company profile